We'll know more about the company's medium-term prospects by the end of the year.

Any fund focused on a specific equity sector faces risk specific to that particular investment group. A biotech fund can be especially volatile, as this fund's performance has demonstrated over the ...

FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...

Launched on January 31, 2006, the State Street SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the ...

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

Mon, August 4, 2025 at 11:15 AM UTC Viking Therapeutics (NASDAQ: VKTX) represents exactly this type of overlooked opportunity, trading at a valuation of just $3.7 billion as of Aug. 1, despite owning ...

Large-cap biotech stocks face patent cliffs and biosimilar competition rather than AI-driven disruption, but companies like Amgen and AbbVie with broad product portfolios and multi-year pipeline ...

The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine, as global R&D investment approaches $360 billion ...

Vir Biotechnology, Inc. (NASDAQ:VIR) is one of the must-buy small cap stocks to buy. On April 13, Vir Biotechnology, Inc.